Rallybio Corporation
RLYB
$0.626
$0.0325.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 761.00K | 848.00K | 636.00K | 598.00K | 299.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 761.00K | 848.00K | 636.00K | 598.00K | 299.00K |
| Cost of Revenue | 21.97M | 22.12M | 27.33M | 35.87M | 40.92M |
| Gross Profit | -21.21M | -21.27M | -26.70M | -35.27M | -40.62M |
| SG&A Expenses | 16.74M | 16.93M | 18.33M | 19.25M | 21.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.16M | 51.23M | 57.83M | 67.30M | 74.30M |
| Operating Income | -43.40M | -50.38M | -57.20M | -66.70M | -74.00M |
| Income Before Tax | -41.65M | -48.19M | -57.78M | -66.97M | -73.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.65 | -48.19 | -57.78 | -66.97 | -73.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.65M | -48.19M | -57.78M | -66.97M | -73.88M |
| EBIT | -43.40M | -50.38M | -57.20M | -66.70M | -74.00M |
| EBITDA | -43.29M | -50.26M | -57.07M | -66.56M | -73.86M |
| EPS Basic | -0.93 | -1.08 | -1.34 | -1.59 | -1.79 |
| Normalized Basic EPS | -0.58 | -0.68 | -0.79 | -0.94 | -1.07 |
| EPS Diluted | -0.93 | -1.08 | -1.34 | -1.59 | -1.79 |
| Normalized Diluted EPS | -0.58 | -0.68 | -0.79 | -0.94 | -1.07 |
| Average Basic Shares Outstanding | 178.87M | 178.16M | 174.16M | 170.13M | 166.07M |
| Average Diluted Shares Outstanding | 178.87M | 178.16M | 174.16M | 170.13M | 166.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |